Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1976 Dec;26(3):601–608.

The heterocytotoxicity of human serum. III. Studies of the serum levels and distribution of activity in human populations.

G Glumac, A Mates, D Eidinger
PMCID: PMC1540972  PMID: 827405

Abstract

A metabolic inhibition assay has been employed to investigate the distribution of serum heterocytotoxicity mediated by natural antibody activating the classical complement pathway and by antibody-independent activation of the alternative complement pathway in human serum samples derived from various groups of individuals. Levels in female cancer patients and in women taking oral contraceptives were significantly elevated over normal controls. Newborn infants exhibited approximately half of the average adult levels. Levels were maximally elevated in patients with visceral cancer, particularly in individuals with adenocarcinomas, while patients with sarcomas exhibited reduced levels. These and other data derived from the literature suggest that the metabolic inhibition assay may provide a useful measure of natural antibody and activation of the alternate complement pathway representative of mechanisms of natural immunity vs tumours.

Full text

PDF
601

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AINIS H., KURTZ H. M., KRAMER P. I., WEIMER H. E., RYAN R. M., JAMESON E. In vivo and in vitro studies of the action of guinea pig serum against the ascites form of the MurphySturm lymphosarcoma. Cancer Res. 1958 Dec;18(11):1309–1313. [PubMed] [Google Scholar]
  2. APTEKMAN P. M., BOGDEN A. E. Characterization of the natural hemagglutinins in normal rat serum associated with a negative phase following tumor implantation. Cancer Res. 1956 Mar;16(3):216–221. [PubMed] [Google Scholar]
  3. Adinolfi M., Beck S. E. Human complement C7 and C9 in fetal and newborn sera. Arch Dis Child. 1975 Jul;50(7):562–564. doi: 10.1136/adc.50.7.562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. BALTCH A. L., HASSIRDJIAN A., OSBORNE W., BUNN P. A. Comparison of properdin titers in sera of normal subjects and patients with leukemia and lymphoma by zymosan and bacteriophage assavs. J Lab Clin Med. 1961 Mar;57:420–427. [PubMed] [Google Scholar]
  5. BOGDEN A. E., APTEKMAN P. M. Disappearance of natural heterogglutinins for human erythrocytes from the sera of rats with progressively growing tumors. Cancer Res. 1953 Dec;13(12):890–894. [PubMed] [Google Scholar]
  6. BOLANDE R. P., TODD E. W. The cytotoxic action of normal human serum on certain human cells propagated in vitro. AMA Arch Pathol. 1958 Dec;66(6):720–732. [PubMed] [Google Scholar]
  7. BOYSE E. A., OLD L. J., STOCKERT E. Inhibitory effect of guinea pig serum on a number of new leukaemias in mice. Nature. 1963 May 25;198:800–800. doi: 10.1038/198800a0. [DOI] [PubMed] [Google Scholar]
  8. BROOME J. D. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J Exp Med. 1963 Jul;118:99–120. doi: 10.1084/jem.118.1.99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Boenisch T., Alper C. A. Isolation and properties of a glycine-rich beta-glycoprotein of human serum. Biochim Biophys Acta. 1970 Dec 22;221(3):529–535. doi: 10.1016/0005-2795(70)90224-2. [DOI] [PubMed] [Google Scholar]
  10. Brai M., Giambanco V., Waks H., Albano V., Osler A. G. Activity levels of the alternate complement pathway in human pregnancy. Acta Eur Fertil. 1974 Mar;5(1):59–64. [PubMed] [Google Scholar]
  11. Brai M., Osler A. G. Cobra venom-induced hemolysis. Activity levels in sera of patients with neoplastic and other diseases. J Exp Med. 1972 Oct 1;136(4):950–955. doi: 10.1084/jem.136.4.950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. CAILLEAU R., KIRK P. L. Some factors affecting the growth-promoting properties of serum in tissue culture. Tex Rep Biol Med. 1957;15(2):237–249. [PubMed] [Google Scholar]
  13. Day N. K., Pickering R. J., Gewurz H., Good R. A. Ontogenetic development of the complement system. Immunology. 1969 Mar;16(3):319–326. [PMC free article] [PubMed] [Google Scholar]
  14. FEDOROFF S., DOERR J. Effect of human blood serum on tissue cultures. III. A natural cytotoxic system in human blood serum. J Natl Cancer Inst. 1962 Aug;29:331–353. [PubMed] [Google Scholar]
  15. GINSBURG I., DISHON T., BLOCK M., GROSS J. A thermostable cytotoxic factor in normal human serum active against Landschutz ascities tumor cells. Proc Soc Exp Biol Med. 1961 Jun;107:235–240. doi: 10.3181/00379727-107-26588. [DOI] [PubMed] [Google Scholar]
  16. GRIFFITHS L. L., RAO C. K., SWIFT P. N. The properdin content of maternal and infant blood. Arch Dis Child. 1962 Dec;37:596–597. doi: 10.1136/adc.37.196.596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Goodkofsky I., Lepow I. H. Functional relationship of factor B in the properdin system to C3 proactivator of human serum. J Immunol. 1971 Oct;107(4):1200–1204. [PubMed] [Google Scholar]
  18. Götze O., Müller-Eberhard H. J. The C3-activator system: an alternate pathway of complement activation. J Exp Med. 1971 Sep 1;134(3 Pt 2):90s–108s. [PubMed] [Google Scholar]
  19. HARTVEIT F. VARIATIONS IN THE ONCOLYTIC ACTIVITY OF HUMAN SERUM. Acta Pathol Microbiol Scand. 1964;62:557–561. doi: 10.1111/apm.1964.62.4.557. [DOI] [PubMed] [Google Scholar]
  20. HIRSCH J. G. Comparative bactericidal activities of blood serum and plasma serum. J Exp Med. 1960 Jul 1;112:15–22. doi: 10.1084/jem.112.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hotham-Iglewski B., Ludwig E. H. A cytocidal system in normal human serum active against Ehrlich Lettré ascites tumor cells. I. Identification of the components of the system and site of attachment. Cancer Res. 1967 Jan;27(1):181–184. [PubMed] [Google Scholar]
  22. IMAGAWA D. T., SYVERTON J. T., BITTNER J. J. The cytotoxicity of serum for mouse mammary cancer cells. I. The effects of admixture in vitro upon homiotransplantability. Cancer Res. 1954 Jan;14(1):1–7. [PubMed] [Google Scholar]
  23. Jasser S., Bragiel I. Behavior of natural immunity factors in relation to age. Arch Immunol Ther Exp (Warsz) 1968;16(1):73–79. [PubMed] [Google Scholar]
  24. Jasser S., Zaorska B. Studies on the level of properdin and complement in the course of neoplasm in children. Pol Med J. 1966;5(4):840–845. [PubMed] [Google Scholar]
  25. KURU M., KOSAKI G., ITOUZI H., ISIBASI H., TOKUNAGA A. The mechanism of cytolysis of Ehrlich ascites tumour brought into contact with normal human serum. Acta Unio Int Contra Cancrum. 1959;15(Suppl 1):165–170. [PubMed] [Google Scholar]
  26. LANDY M., MICHAEL J. G., TRAPANI R. J., ACHINSTEIN B., WOODS M. W., SHEAR M. J. An antibody-complement system in normal serum lethal to mouse tumor cells. Cancer Res. 1960 Oct;20:1279–1291. [PubMed] [Google Scholar]
  27. Laskov R., Simon E., Gross J. Studies on a naturally occurring human antibody active against mouse Landschutz ascites tumor cells. I. Cytotoxicity assay system and quantitation in normal sera. Int J Cancer. 1968 Jan 15;3(1):96–106. doi: 10.1002/ijc.2910030112. [DOI] [PubMed] [Google Scholar]
  28. MILLER D. G., HSU T. C. The action of cytotoxic antisera on the HeLa strain of human carcinoma. Cancer Res. 1956 May;16(4):306–312. [PubMed] [Google Scholar]
  29. Occhino J. C., Glasgow A. H., Cooperband S. R., Mannick J. A., Schmid K. Isolation of an immunosuppressive peptide fraction from human plasma. J Immunol. 1973 Mar;110(3):685–694. [PubMed] [Google Scholar]
  30. PENTTINEN K., SAXEN E. Growth-controlling action of human serum in cell culture. Nature. 1959 Nov 14;184(Suppl 20):1570–1571. doi: 10.1038/1841570b0. [DOI] [PubMed] [Google Scholar]
  31. PIKOVSKI M., SCHLESINGER M. Natural agglutinis in rat sera against cells of mouse tumors differing in their transplantability to pretreated rats. Cancer Res. 1959 Feb;19(2):227–232. [PubMed] [Google Scholar]
  32. PILLEMER L., BLUM L., LEPOW I. H., ROSS O. A., TODD E. W., WARDLAW A. C. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science. 1954 Aug 20;120(3112):279–285. doi: 10.1126/science.120.3112.279. [DOI] [PubMed] [Google Scholar]
  33. PILLEMER L., SCHOENBERG M. D., BLUM L., WURZ L. Properdin system and immunity. II. Interaction of the properdin system with polysaccharides. Science. 1955 Sep 23;122(3169):545–549. doi: 10.1126/science.122.3169.545. [DOI] [PubMed] [Google Scholar]
  34. RADZIKHOVSKAIA R. M. Rol' antitel protivoopukholevom immunitete. Vopr Onkol. 1958;4(2):234–244. [PubMed] [Google Scholar]
  35. REJNEK J., BEDNARIK T., RERABKOVA E., DOLEZAL A. Investigations of the influence of sera from pregnant women on the growth of cell cultures in conjunction with the occurrence of abnormal alpha-lipoprotein. Clin Chim Acta. 1963 Jan;8:108–115. doi: 10.1016/0009-8981(63)90205-5. [DOI] [PubMed] [Google Scholar]
  36. Rogentine G. N., Jr, Plocinik B. A. Carbohydrate inhibition studies of the naturally occurring human antibody to neuraminidase-treated human lymphocytes. J Immunol. 1974 Sep;113(3):848–858. [PubMed] [Google Scholar]
  37. Rogentine N., Jr Naturally occurring human antibody to neuraminidase-treated human lymphocytes. Antibody levels in normal subjects, cancer patients, and subjects with immunodeficiency. J Natl Cancer Inst. 1975 Jun;54(6):1307–1311. doi: 10.1093/jnci/54.6.1307. [DOI] [PubMed] [Google Scholar]
  38. Rosenberg S. A., Rogentine G. N., Jr Natural human antibodies to "hidden" membrane components. Nat New Biol. 1972 Oct 18;239(94):203–204. doi: 10.1038/newbio239203a0. [DOI] [PubMed] [Google Scholar]
  39. SOUTHAM C. M., PILLEMER L. Serum properdin levels and cancer cell homografts in man. Proc Soc Exp Biol Med. 1957 Dec;96(3):596–601. doi: 10.3181/00379727-96-23550. [DOI] [PubMed] [Google Scholar]
  40. TERASAKI P. I., ESAIL M. L., CANNON J. A., LONGMIRE W. P., Jr Destruction of lymphocytes in vitro by normal serum from common laboratory animals. J Immunol. 1961 Oct;87:383–395. [PubMed] [Google Scholar]
  41. TROEH M. R., SLATER C. R., LARSON W. M., Jr, McKEE R. W. Changes in serum properdin of mice during tumor growth and following immunization to Ehrlich ascites carcinoma. Proc Soc Exp Biol Med. 1962 Jan;109:51–54. doi: 10.3181/00379727-109-27101. [DOI] [PubMed] [Google Scholar]
  42. Veit B., Michael J. G. Characterization of an immunosuppressive factor present in mouse serum. J Immunol. 1973 Aug;111(2):341–351. [PubMed] [Google Scholar]
  43. WILLHEIM R., REVICI E., FLUSS P., AUBER M. Further experiments concerning the lytic power of blood serum against ascites tumor cells. Exp Med Surg. 1959;17:272–281. [PubMed] [Google Scholar]
  44. Whitney R. B., Levy J. G. Effects of sera from tumor-bearing mice on mitogen and allogeneic cell stimulation of normal lymphoid cells. J Natl Cancer Inst. 1975 Mar;54(3):733–741. [PubMed] [Google Scholar]
  45. Wohl H., Ghossein N. A. Complement levels before and after radiotherapy in cancer patients. Oncology. 1971;25(4):344–346. doi: 10.1159/000224583. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES